Trevi's chronic cough trial in IPF subjects continues without sample size change [Yahoo! Finance]
Trevi Therapeutics, Inc. (TRVI)
Company Research
Source: Yahoo! Finance
pulmonary fibrosis (IPF) subjects with chronic cough, will continue with its current sample size of 160 participants. This decision follows a positive planned sample size re-estimation (SSRE) analysis. It was carried out on the highest dose group, receiving 108mg of Haduvio two times a day, after half of the targeted enrolment completed the six-week treatment. The analysis concluded that the trial should proceed as initially planned, ensuring a conditional power of 80% or higher. The SSRE also considered other potential outcomes such as increasing the sample size or declaring the trial futile, but neither of these actions was recommended. The double-blind, placebo-controlled, parallel-arm, randomised study aims to assess three doses of the therapy against a placebo in individuals with the given condition. Around 160 IPF subjects with chronic cough are being randomised to receive one of the three doses of Haduvio or a placebo for a period of six weeks. This includes a two-wee
Show less
Read more
Impact Snapshot
Event Time:
TRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRVI alerts
High impacting Trevi Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRVI
News
- Trevi Therapeutics Announces Pricing of $50 Million Underwritten OfferingPR Newswire
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.MarketBeat
- Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? [Yahoo! Finance]Yahoo! Finance
TRVI
Earnings
- 11/6/24 - Miss
TRVI
Sec Filings
- 12/17/24 - Form 4
- 12/16/24 - Form 8-K
- 12/16/24 - Form 424B5
- TRVI's page on the SEC website